All In Biotech

Drug Trial Radar · NCT01776424

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).

Last checked: Nov 19, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 27,395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

27,395

Actual

Start

Feb 28, 2013

Primary completion

Jul 21, 2017

Study completion Jun 15, 2021

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Population Health Research Institute; Janssen Research & Development, LLC
First posted
Jan 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are: * To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD); * To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.

Conditions

  • Prevention & Control

Interventions

  • Rivaroxaban (Xarelto, BAY59-7939)Drug

    Tablet, 2.5 mg, twice daily, oral

  • Rivaroxaban (Xarelto, BAY59-7939)Drug

    Tablet, 5 mg, twice daily, oral

  • AspirinDrug

    Tablet, 100 mg, once daily, oral

  • Aspirin placeboDrug

    Aspirin matching placebo, once daily, oral

  • Rivaroxaban placeboDrug

    Rivaroxaban matching placebo, twice daily, oral

  • PantoprazoleDrug

    Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole

  • Pantoprazole placeboDrug

    Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) DeathTime frame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
  2. The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) CriteriaTime frame: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

Locations

565 sites in 33 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Anaheim, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Northridge, California

  • Site not named

    Palo Alto, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Sylmar, California

  • Site not named

    Torrance, California

  • Site not named

    Norwalk, Connecticut

  • Site not named

    Stamford, Connecticut

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Atlantis, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Coral Springs, Florida

  • Site not named

    Jacksonville Beach, Florida

  • Site not named

    Largo, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Safety Harbor, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Meridian, Idaho

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Hazel Crest, Illinois

  • Site not named

    Davenport, Iowa

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Crestview Hills, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Haverhill, Massachusetts

  • Site not named

    Alpena, Michigan

  • Site not named

    Jackson, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Kalispell, Montana

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Cortlandt Manor, New York

  • Site not named

    Kingston, New York

  • Site not named

    Saratoga Springs, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Pinehurst, North Carolina

  • Site not named

    Elyria, Ohio

  • Site not named

    Sandusky, Ohio

Showing 40 of 565 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.